PL1924264T3 - Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub> - Google Patents
Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub>Info
- Publication number
- PL1924264T3 PL1924264T3 PL06778331T PL06778331T PL1924264T3 PL 1924264 T3 PL1924264 T3 PL 1924264T3 PL 06778331 T PL06778331 T PL 06778331T PL 06778331 T PL06778331 T PL 06778331T PL 1924264 T3 PL1924264 T3 PL 1924264T3
- Authority
- PL
- Poland
- Prior art keywords
- diaminopyrimidines
- modulators
- Prior art date
Links
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 title 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71354805P | 2005-09-01 | 2005-09-01 | |
| PCT/EP2006/065606 WO2007025925A1 (en) | 2005-09-01 | 2006-08-23 | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP06778331.6A EP1924264B9 (en) | 2005-09-01 | 2006-08-23 | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1924264T3 true PL1924264T3 (pl) | 2014-03-31 |
Family
ID=37492274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06778331T PL1924264T3 (pl) | 2005-09-01 | 2006-08-23 | Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub> |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8008313B2 (pl) |
| EP (1) | EP1924264B9 (pl) |
| JP (1) | JP4850914B2 (pl) |
| KR (1) | KR101012926B1 (pl) |
| CN (1) | CN101300012B (pl) |
| AU (1) | AU2006286601B2 (pl) |
| BR (1) | BRPI0615040A2 (pl) |
| CA (1) | CA2620034C (pl) |
| DK (1) | DK1924264T5 (pl) |
| ES (1) | ES2439454T3 (pl) |
| IL (1) | IL189499A (pl) |
| MX (1) | MX2008002733A (pl) |
| PL (1) | PL1924264T3 (pl) |
| SI (1) | SI1924264T1 (pl) |
| WO (1) | WO2007025925A1 (pl) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2391636T3 (es) * | 2004-03-05 | 2012-11-28 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como antagonistas de P2X3 y P2X2/3 |
| AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| JP5113752B2 (ja) | 2005-08-22 | 2013-01-09 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
| EP1924264B9 (en) * | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| BRPI0615613A2 (pt) * | 2005-09-01 | 2009-05-19 | Hoffmann La Roche | diaminopirimidinas como moduladores de p2x3 e p3x2/3 |
| ES2461595T3 (es) * | 2006-10-04 | 2014-05-20 | F. Hoffmann-La Roche Ag | Proceso para la síntesis de derivados de fenoxi-diaminopirimidina |
| AU2007307638A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| CN103271906A (zh) | 2006-10-12 | 2013-09-04 | 泽农医药公司 | 螺-吲哚酮化合物作为治疗剂的用途 |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| US8101644B2 (en) | 2007-03-30 | 2012-01-24 | Shionogi & Co., Ltd. | Pyrrolinone derivative and pharmaceutical composition comprising the same |
| AU2008279242A1 (en) * | 2007-07-23 | 2009-01-29 | Melior Discovery, Inc. | Methods of activating IRS-1 and AKT |
| US8247401B2 (en) | 2007-10-31 | 2012-08-21 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| US8946439B2 (en) | 2008-02-29 | 2015-02-03 | Evotec Ag | Amide compounds, compositions and uses thereof |
| US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2010035727A1 (ja) | 2008-09-25 | 2010-04-01 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
| CN103664973B (zh) * | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| US8101647B2 (en) * | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8598209B2 (en) | 2008-10-31 | 2013-12-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| PL2399910T3 (pl) | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| JP2012521428A (ja) | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のｐ２ｘ３受容体アンタゴニスト |
| ES2660892T3 (es) | 2009-03-23 | 2018-03-26 | Merck Sharp & Dohme Corp. | Antagonistas del receptor P2X3 para el tratamiento del dolor |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| WO2011047173A2 (en) * | 2009-10-14 | 2011-04-21 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| US8445696B2 (en) * | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| BR112012021086A2 (pt) | 2010-02-26 | 2016-05-17 | Xenon Pharmaceuticals Inc | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| BR112013002984B1 (pt) | 2010-08-10 | 2021-10-26 | Shionogi & Co., Ltd | Compostos derivados de triazina e composições farmacêuticas que os compreendem |
| US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
| US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
| WO2013154712A1 (en) | 2012-04-12 | 2013-10-17 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| SG11201601145RA (en) * | 2013-08-23 | 2016-03-30 | Afferent Pharmaceuticals Inc | Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough |
| WO2016004358A1 (en) | 2014-07-03 | 2016-01-07 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| CN104447574A (zh) * | 2014-12-26 | 2015-03-25 | 苏州步跃医药科技有限公司 | 一种奥美普林的合成方法 |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| EP3355889B1 (en) | 2015-09-29 | 2023-02-15 | Afferent Pharmaceuticals Inc. | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| RU2761439C2 (ru) * | 2016-03-14 | 2021-12-08 | Эфферент Фармасьютикалз Инк. | Пиримидины, их варианты и применение |
| EP3433258B1 (en) * | 2016-03-25 | 2023-07-19 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| JP6934945B2 (ja) * | 2016-12-20 | 2021-09-15 | アファレント ファーマシューティカルズ インコーポレイテッド | Ｐ２ｘ３アンタゴニストの結晶塩および多形 |
| JP7182605B2 (ja) | 2017-04-10 | 2022-12-02 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | ｌｙｎキナーゼ活性化因子及びＴＲＰＭ８アゴニストを含む組成物及び医薬の製造におけるそれらの使用 |
| CN109761910B (zh) * | 2018-12-04 | 2021-11-19 | 华中农业大学 | 一种艾地普林的合成方法 |
| GEP20257823B (en) | 2019-05-31 | 2025-11-10 | Chiesi Farm Spa | Amino quinazoline derivatives as p2x3 inhibitors |
| WO2020239953A1 (en) * | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Pyridopyrimidines derivatives as p2x3 inhibitors |
| CN113924293B (zh) * | 2019-06-06 | 2024-07-09 | 北京泰德制药股份有限公司 | P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途 |
| CA3159689C (en) * | 2019-11-29 | 2025-05-27 | Wuhan Ll Science And Technology Development Co., Ltd. | COMPOUND CONTAINING AN ORTHOCODENSE HETEROCYCLE AND USE AS A P2X4 ANTAGONIST |
| US11607395B2 (en) * | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| TWI849314B (zh) * | 2020-06-01 | 2024-07-21 | 日商住友化學股份有限公司 | 化合物、樹脂、抗蝕劑組成物及抗蝕劑圖案的製造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
| SE9701304D0 (sv) * | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
| US6583148B1 (en) * | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| JP2005508182A (ja) | 2001-11-09 | 2005-03-31 | アルゴス セラピューティクス，インコーポレーテッド | プリノレセプターｐ２ｘ３のアンチセンス調節 |
| ES2391636T3 (es) * | 2004-03-05 | 2012-11-28 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como antagonistas de P2X3 y P2X2/3 |
| CA2573565A1 (en) * | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| CA2620129C (en) * | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP1924564B1 (en) * | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP1924264B9 (en) * | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| BRPI0615613A2 (pt) * | 2005-09-01 | 2009-05-19 | Hoffmann La Roche | diaminopirimidinas como moduladores de p2x3 e p3x2/3 |
-
2006
- 2006-08-23 EP EP06778331.6A patent/EP1924264B9/en active Active
- 2006-08-23 MX MX2008002733A patent/MX2008002733A/es active IP Right Grant
- 2006-08-23 AU AU2006286601A patent/AU2006286601B2/en active Active
- 2006-08-23 WO PCT/EP2006/065606 patent/WO2007025925A1/en not_active Ceased
- 2006-08-23 SI SI200631683T patent/SI1924264T1/sl unknown
- 2006-08-23 DK DK06778331.6T patent/DK1924264T5/en active
- 2006-08-23 CA CA2620034A patent/CA2620034C/en active Active
- 2006-08-23 CN CN2006800405247A patent/CN101300012B/zh active Active
- 2006-08-23 ES ES06778331.6T patent/ES2439454T3/es active Active
- 2006-08-23 KR KR1020087007681A patent/KR101012926B1/ko active Active
- 2006-08-23 PL PL06778331T patent/PL1924264T3/pl unknown
- 2006-08-23 BR BRPI0615040-3A patent/BRPI0615040A2/pt not_active Application Discontinuation
- 2006-08-23 JP JP2008528482A patent/JP4850914B2/ja active Active
- 2006-08-25 US US11/509,921 patent/US8008313B2/en active Active
-
2008
- 2008-02-13 IL IL189499A patent/IL189499A/en active IP Right Grant
-
2011
- 2011-07-19 US US13/186,078 patent/US8524725B2/en active Active
-
2013
- 2013-04-19 US US13/866,212 patent/US20130225570A1/en not_active Abandoned
-
2016
- 2016-06-01 US US15/170,666 patent/US20160271131A1/en not_active Abandoned
-
2018
- 2018-07-05 US US16/028,365 patent/US20180311240A1/en not_active Abandoned
-
2020
- 2020-09-25 US US17/032,489 patent/US20210008071A1/en not_active Abandoned
-
2024
- 2024-07-22 US US18/779,395 patent/US20250025462A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK1924264T5 (en) | 2014-03-24 |
| CN101300012A (zh) | 2008-11-05 |
| MX2008002733A (es) | 2008-03-26 |
| WO2007025925A1 (en) | 2007-03-08 |
| US20120122859A1 (en) | 2012-05-17 |
| US20130225570A1 (en) | 2013-08-29 |
| KR101012926B1 (ko) | 2011-02-09 |
| KR20080049802A (ko) | 2008-06-04 |
| SI1924264T1 (sl) | 2013-12-31 |
| US8008313B2 (en) | 2011-08-30 |
| US8524725B2 (en) | 2013-09-03 |
| ES2439454T9 (es) | 2014-03-07 |
| EP1924264A1 (en) | 2008-05-28 |
| IL189499A (en) | 2013-05-30 |
| IL189499A0 (en) | 2008-08-07 |
| US20070049609A1 (en) | 2007-03-01 |
| DK1924264T3 (da) | 2013-10-21 |
| CN101300012B (zh) | 2011-09-14 |
| US20160271131A1 (en) | 2016-09-22 |
| US20180311240A1 (en) | 2018-11-01 |
| EP1924264B9 (en) | 2014-02-19 |
| EP1924264B1 (en) | 2013-09-18 |
| BRPI0615040A2 (pt) | 2011-04-26 |
| JP2009507000A (ja) | 2009-02-19 |
| AU2006286601A1 (en) | 2007-03-08 |
| ES2439454T3 (es) | 2014-01-23 |
| JP4850914B2 (ja) | 2012-01-11 |
| AU2006286601B2 (en) | 2012-07-05 |
| CA2620034C (en) | 2013-10-01 |
| US20250025462A1 (en) | 2025-01-23 |
| US20210008071A1 (en) | 2021-01-14 |
| CA2620034A1 (en) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189499A0 (en) | Diaminopyrimidines as p2x3 and p2x2/3 modulators | |
| IL189500A0 (en) | Diaminopyrimidines as p2x3 and p3x2/3 modulators | |
| IL217453A0 (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists | |
| IL184111A0 (en) | Prostaglandin-containing compositions and methods for enhancing the stability thereof | |
| EP1945820A4 (en) | TOLL 3 RECEPTOR MODULATORS, AND METHODS AND USES THEREOF | |
| GB0507114D0 (en) | No 1 timemachine | |
| GB0509703D0 (en) | Hayfit 2 | |
| IL192247A0 (en) | Phosphorylated cop1 molecules and uses thereof | |
| EP1906960A4 (en) | NEW COMBINATION 1 | |
| GB0514559D0 (en) | Qmaster 2005 | |
| GB0518344D0 (en) | I c v t 2005 | |
| GB0507341D0 (en) | The invisible bridge | |
| GB2440780B (en) | The rula | |
| GB0616698D0 (en) | Ladderfix 2 | |
| GB0512493D0 (en) | iCorcost 5 | |
| GB0514110D0 (en) | iCorcost 8 | |
| GB0512524D0 (en) | iCorcost 6 | |
| GB0515077D0 (en) | iCorcost 9 | |
| GB0515197D0 (en) | Freshbox 100 | |
| GB0515524D0 (en) | iCorcost 10 | |
| GB0517452D0 (en) | iCorcost 5 | |
| GB0517579D0 (en) | Corcost 8 | |
| GB0517586D0 (en) | Corcost 6 | |
| GB0519041D0 (en) | Rollec 2 | |
| GB0520322D0 (en) | Webhead 2 |